摘要
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder. In this study, we investigated the characteristics of bortezomib-induced taste disorder and the underlying mechanism in mice. Among the five basic tastes, the sour taste sensitivity of mice was significantly increased by bortezomib administration. In bortezomib-administered mice, protein expression of PKD2L1 was increased. The increased sour taste sensitivity induced by bortezomib returned to the control level on cessation of its administration. These results suggest that an increase in protein expression of PKD2L1 enhances the sour taste sensitivity in bortezomib-administered mice, and this alteration is reversed on cessation of its administration.
摘要译文
化疗引起的味觉障碍是癌症治疗中的关键问题之一。硼替佐米是一种蛋白酶体抑制剂，是多发性骨髓瘤疗法的关键药物，但会诱发味觉障碍。在这项研究中，我们调查了硼替佐米诱发的味觉障碍的特征和小鼠的潜在机制。在五种基本口味中，硼替佐米给药后小鼠的酸味敏感性显着增加。在硼替佐米给药的小鼠中，PKD2L1的蛋白质表达增加。硼替佐米引起的酸味增加的敏感性在停止给药时恢复到对照水平。这些结果表明PKD2L1的蛋白质表达的增加增强硼替佐米给药小鼠的酸味敏感性，并且在停止给药时这种改变被逆转。
AkihiroOhishi;KentaroNishida;KarinMiyamoto;MizukaImai;RyokoNakanishi;KyokoKobayashi;AkikoHayashi;KazukiNagasawa;. Bortezomib alters sour taste sensitivity in mice[J]. Toxicology Reports, 2017,4: 172-180